New Drug Approvals

Home » COMPANIES » Christopher Conway has been appointed to lead AMRI ’s discovery business strategy as SrVP of Discovery and Development and Global Commercial Sales.

Christopher Conway has been appointed to lead AMRI ’s discovery business strategy as SrVP of Discovery and Development and Global Commercial Sales.



Read all about Organic Spectroscopy on ORGANIC SPECTROSCOPY INTERNATIONAL 


Blog Stats

  • 2,699,557 hits

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 2,441 other followers

add to any


Christopher Conway

Christopher Conway, Senior Vice President,
Global Sales and Marketing

Christopher Conway has been appointed to lead the company’s discovery business strategy as Senior Vice President of Discovery and Development and Global Commercial Sales.

September 3, 2015




Dear industry colleague,

As we continue to support the research and development that leads to the commercialization of pharmaceutical products, it is critical that we align our focus on R&D with the commercial demands of the market. Today, AMRI has announced an organizational change in our Discovery and Development Services (DDS) business. These changes are expected to drive top and bottom line growth for the Discovery and Development Solutions (DDS) business through strong commercial leadership; strengthen the DDS strategy and aggressively pursue the most valuable growth opportunities, externally and internally; and ensure that our service offerings are well aligned with your needs and the needs of the market.

Effective immediately, Christopher Conway has been appointed to lead the company’s discovery business strategy as Senior Vice President of Discovery and Development and Global Commercial Sales. In this role, Chris will head up the global Discovery and Development Solutions (DDS) business leading these businesses in the United States, Europe and Asia. Sales and marketing will also continue to report to him. He succeeds Michael A. Luther, Ph.D., MBA, who will be leaving AMRI to pursue other opportunities. We thank Dr. Luther for his efforts in moving the DDS business along over the last year and wish him the best in his future endeavors.

Related to this announcement, we would like to take the opportunity to announce the hiring of Rory Curtis, Ph.D., who has joined AMRI as Vice President of Discovery Biology and Pharmacology. Rory will also serve as site head with responsibility for scientific operations at AMRI’s Buffalo, N.Y. location. Rory was most recently Senior Director of Human Diseases in Discovery at Cubist Pharmaceuticals, where he developed Cubist’s antibacterial drug discovery into new disease areas such as pain, inflammation and gastro-intestinal disease. Before this, he held positions of increasing responsibility at Elixir Pharmaceuticals, Millennium Pharmaceuticals and Regeneron Pharmaceuticals.

Rory Curtis

Rory Curtis

Vice President of Discovery Biology and Pharmacology, Site Head AMRI Buffalo

In addition to Chris’ current direct reports and Rory, he will have a scientific leadership team reporting into him, which includes Michael P. Trova, Ph.D., Senior Vice President of Chemistry; Raj Shenoy, Senior Director of Global Chemical Development; and Pete Michels, Ph.D., Senior Director of Metabolism and Biotransformations.

Michael P. Trova, Ph.D.

Pete C. Michels, Ph.D., Senior Director, Chemical Development, Fermentation and Biocatalysis, AMRI

We are very excited about the future of AMRI Drug Discovery and Development and are pleased to welcome Rory to the AMRI discovery team. Market demand for our DDS services continues to grow and these changes will help us increase our market share and strengthen AMRI’s global position in Discovery and Development.

As we approach the second half of 2015, we are looking forward to working with you on a great number of new opportunities in 2016 and beyond. We appreciate your loyalty and support, and continue to remain dedicated to enhancing your pharmaceutical services experience from early discovery through to the commercialization and delivery of drug product. If you have any questions, please feel free to read today’s related press release at, or contact us here.



William S. Marth
President and CEO
Albany Molecular Research Inc. (AMRI)

William S. Marth. President and Chief Executive Officer Albany Molecular Research, Inc.


Albany Molecular Research Locations
Albany Molecular Research Inc. (AMRI)
26 Corporate Circle
Albany, NY 12203

Albany Molecular Research Inc. provides global contract research and manufacturing services to the pharmaceutical and biotechnology industries. Our services include Drug Discovery, such as medicinal chemistry, discovery biology and in vitro ADME; Development, such as pre-formulation, formulation and validation; and Manufacturing, such as cGMP API manufacturing.



AMRI SingaporeAMRI’s Singapore Research Centre, Pte. Ltd. provides chemistry and biology services to support drug discovery and development programs. AMRI is one of the first drug discovery R&D companies to establish operations in Singapore. Fully integrated with AMRI’s locations in the United States, Asia, and Europe, the Singapore centre offers medicinal chemistry services such as hit-to-lead andlead optimization as well as focused library synthesis / custom synthesis. In the area of biology / in vitro pharmacology, the Singapore Research Centre provides target validation; assay development; HTS; rapid production of SAR quality data; and in vitro ADMET support, including CYP inhibition, metabolic stability (liver microsome assays), and aqueous solubility. As a signatory to the World Patent Treaty, Singapore provides an environment that protects intellectual property, enabling our scientists to conduct proprietary and cutting-edge research on behalf of our customers.

Areas of Expertise: Discovery Services

Contact Information:
61 Science Park Road
#05-01 The Galen
Singapore Science Park II
Singapore 117525

Phone: +65-6398-5500
Fax: +65-6398-5511



AMRI Hyderabad IndiaThe Hyderabad Research Centre, Pvt. Ltd. (AMRHRC) is located in Hyderabad, India, an emerging technology metropolis located in South Central India.

All fully integrated with AMRI’s U.S.-based resources, this Centre’s core area of expertise is in the areas of medicinal chemistrysupport, chemical development, custom synthesis of scaffolds and building blocks, process development, GMP analytical services,scale-up and preparation of reference standards.

Areas of Expertise: Chemical Development and Small Scale Manufacturing

Contact Information:
Hyderabad Research Centre Pvt. Ltd.
Plot # 9, Alexandria Knowledge Park, Turkapally, Shameerpet
Genome Valley, RR District, Hyderabad – 500 078, India

Tel : +91 – 40 – 6687 6666  (Board)
Fax : +91 – 40 – 6687 6600


GRANT CARR, PH.D. Follow Grant Carr at Linked In


Robert Kargbo, Ph.D.

ROBERT B. KARGBO, PH.D. linkedin


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

This site uses Akismet to reduce spam. Learn how your comment data is processed.


Follow New Drug Approvals on

Enter your email address to follow this blog and receive notifications of new posts by email.

Join 2,441 other followers



DR ANTHONY MELVIN CRASTO, Born in Mumbai in 1964 and graduated from Mumbai University, Completed his Ph.D from ICT, 1991,Matunga, Mumbai, India, in Organic Chemistry, The thesis topic was Synthesis of Novel Pyrethroid Analogues, Currently he is working with GLENMARK PHARMACEUTICALS LTD, Research Centre as Principal Scientist, Process Research (bulk actives) at Mahape, Navi Mumbai, India. Total Industry exp 30 plus yrs, Prior to joining Glenmark, he has worked with major multinationals like Hoechst Marion Roussel, now Sanofi, Searle India Ltd, now RPG lifesciences, etc. He has worked with notable scientists like Dr K Nagarajan, Dr Ralph Stapel, Prof S Seshadri, Dr T.V. Radhakrishnan and Dr B. K. Kulkarni, etc, He did custom synthesis for major multinationals in his career like BASF, Novartis, Sanofi, etc., He has worked in Discovery, Natural products, Bulk drugs, Generics, Intermediates, Fine chemicals, Neutraceuticals, GMP, Scaleups, etc, he is now helping millions, has 9 million plus hits on Google on all Organic chemistry websites. His friends call him Open superstar worlddrugtracker. His New Drug Approvals, Green Chemistry International, All about drugs, Eurekamoments, Organic spectroscopy international, etc in organic chemistry are some most read blogs He has hands on experience in initiation and developing novel routes for drug molecules and implementation them on commercial scale over a 30 year tenure till date Dec 2017, Around 35 plus products in his career. He has good knowledge of IPM, GMP, Regulatory aspects, he has several International patents published worldwide . He has good proficiency in Technology transfer, Spectroscopy, Stereochemistry, Synthesis, Polymorphism etc., He suffered a paralytic stroke/ Acute Transverse mylitis in Dec 2007 and is 90 %Paralysed, He is bound to a wheelchair, this seems to have injected feul in him to help chemists all around the world, he is more active than before and is pushing boundaries, He has 9 million plus hits on Google, 2.5 lakh plus connections on all networking sites, 50 Lakh plus views on dozen plus blogs, He makes himself available to all, contact him on +91 9323115463, email, Twitter, @amcrasto , He lives and will die for his family, 90% paralysis cannot kill his soul., Notably he has 19 lakh plus views on New Drug Approvals Blog in 216 countries...... , He appreciates the help he gets from one and all, Friends, Family, Glenmark, Readers, Wellwishers, Doctors, Drug authorities, His Contacts, Physiotherapist, etc

Personal Links

View Full Profile →



Follow my blog with Bloglovin The title of your home page You could put your verification ID in a comment Or, in its own meta tag Or, as one of your keywords Your content is here. The verification ID will NOT be detected if you put it here.
%d bloggers like this: